Cross-source evidence timeline

Ganirelix research timeline

Follow 42 selected, directly cited source records from July 29, 1999 through July 2, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

42Selected records
17Source years
3Evidence lanes
July 2, 2026Latest source date

Source year

2026

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT06745466↗

    PeptideScanner retained ClinicalTrials.gov record NCT06745466 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05954962↗

    PeptideScanner retained ClinicalTrials.gov record NCT05954962 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  3. Literature metadata

    New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model.↗

    PubMed lists PMID 36279721 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2022-10-21 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

5 records
  1. Clinical trials

    ClinicalTrials.gov record NCT03142893↗

    PeptideScanner retained ClinicalTrials.gov record NCT03142893 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT04037605↗

    PeptideScanner retained ClinicalTrials.gov record NCT04037605 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  3. Regulatory

    Drugs@FDA application ANDA219454↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 219454 with status AP dated 2025-06-27, and names ganirelix acetate among the application record's active ingredients.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT05751252↗

    PeptideScanner retained ClinicalTrials.gov record NCT05751252 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  5. Regulatory

    Drugs@FDA application ANDA218855↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 218855 with status AP dated 2025-04-23, and names ganirelix acetate among the application record's active ingredients.↗

Source year

2024

7 records
  1. Clinical trials

    ClinicalTrials.gov record NCT06091436↗

    PeptideScanner retained ClinicalTrials.gov record NCT06091436 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00703014↗

    PeptideScanner retained ClinicalTrials.gov record NCT00703014 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00702273↗

    PeptideScanner retained ClinicalTrials.gov record NCT00702273 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00988260↗

    PeptideScanner retained ClinicalTrials.gov record NCT00988260 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-08-15, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT00696800↗

    PeptideScanner retained ClinicalTrials.gov record NCT00696800 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-06-20, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT01304511↗

    PeptideScanner retained ClinicalTrials.gov record NCT01304511 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-04-03, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  7. Literature metadata

    Molecular characterization, modeling, in silico analysis of equine pituitary gonadotropin alpha subunit and docking interaction studies with ganirelix.↗

    PubMed lists PMID 28721542 in In silico pharmacology as Journal Article, with publication-date metadata of 2017-07-18 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2023

2 records
  1. Regulatory

    Drugs@FDA application ANDA216075↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 216075 with status AP dated 2023-11-16, and names ganirelix acetate among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA215658↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 215658 with status AP dated 2023-02-28, and names ganirelix acetate among the application record's active ingredients.↗

Source year

2022

4 records
  1. Regulatory

    Drugs@FDA application ANDA214996↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 214996 with status AP dated 2022-06-06, and names ganirelix acetate among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA212613↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 212613 with status AP dated 2022-04-07, and names ganirelix acetate among the application record's active ingredients.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00724789↗

    PeptideScanner retained ClinicalTrials.gov record NCT00724789 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-02-03, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT03300518↗

    PeptideScanner retained ClinicalTrials.gov record NCT03300518 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-01-11, and PeptideScanner's reviewed identity mapping was ganirelix.↗

Source year

2020

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00608062↗

    PeptideScanner retained ClinicalTrials.gov record NCT00608062 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00589134↗

    PeptideScanner retained ClinicalTrials.gov record NCT00589134 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-03-30, and PeptideScanner's reviewed identity mapping was ganirelix.↗

Source year

2019

3 records
  1. Literature metadata

    Radioimmunoassay of ganirelix in plasma or serum.↗

    PubMed lists PMID 8354719 in Journal of immunoassay as Comparative Study, Journal Article, with publication-date metadata of 1993-09 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT03051087↗

    PeptideScanner retained ClinicalTrials.gov record NCT03051087 at 2026-11-15T22:03:26.540Z. Its registry update date was 2019-07-02, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  3. Literature metadata

    Ganirelix acetate.↗

    PubMed lists PMID 10582819 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 1999-11-15 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2018

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01153581↗

    PeptideScanner retained ClinicalTrials.gov record NCT01153581 at 2026-11-15T22:03:26.540Z. Its registry update date was 2018-12-13, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  2. Regulatory

    Drugs@FDA application ANDA204246↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 204246 with status AP dated 2018-11-30, and names ganirelix acetate among the application record's active ingredients.↗

  3. Literature metadata

    Ganirelix.↗

    PubMed lists PMID 10718102 in Drugs as Journal Article, Review, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2017

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00734279↗

    PeptideScanner retained ClinicalTrials.gov record NCT00734279 at 2026-11-15T22:03:26.540Z. Its registry update date was 2017-12-26, and PeptideScanner's reviewed identity mapping was ganirelix.↗

Source year

2016

3 records
  1. Literature metadata

    Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'.↗

    PubMed lists PMID 20504085 in Acta obstetricia et gynecologica Scandinavica as Journal Article, Multicenter Study, with publication-date metadata of 2010-06 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00757185↗

    PeptideScanner retained ClinicalTrials.gov record NCT00757185 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-07-04, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01816321↗

    PeptideScanner retained ClinicalTrials.gov record NCT01816321 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-06-23, and PeptideScanner's reviewed identity mapping was ganirelix.↗

Source year

2015

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00225433↗

    PeptideScanner retained ClinicalTrials.gov record NCT00225433 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00780858↗

    PeptideScanner retained ClinicalTrials.gov record NCT00780858 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-05-06, and PeptideScanner's reviewed identity mapping was ganirelix.↗

Source year

2014

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT01645241↗

    PeptideScanner retained ClinicalTrials.gov record NCT01645241 at 2026-11-15T22:03:26.540Z. Its registry update date was 2014-10-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗

Source year

2013

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00823004↗

    PeptideScanner retained ClinicalTrials.gov record NCT00823004 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-12-23, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01286051↗

    PeptideScanner retained ClinicalTrials.gov record NCT01286051 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-03-20, and PeptideScanner's reviewed identity mapping was ganirelix.↗

Source year

2011

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00802360↗

    PeptideScanner retained ClinicalTrials.gov record NCT00802360 at 2026-11-15T22:03:26.540Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was ganirelix.↗

Source year

2008

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00461422↗

    PeptideScanner retained ClinicalTrials.gov record NCT00461422 at 2026-11-15T22:03:26.540Z. Its registry update date was 2008-06-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗

Source year

2004

1 record
  1. Regulatory

    Federal Register notice 04-24378↗

    The Federal Register published notice 04-24378, attributed to FDA and its parent HHS department, on 2004-11-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON),” and PeptideScanner's exact reviewed identity mapping connects the document to Ganirelix.↗

Source year

1999

1 record
  1. Regulatory

    Drugs@FDA application NDA021057↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 021057 with status AP dated 1999-07-29, and names ganirelix acetate among the application record's active ingredients.↗